Basis: Trailing twelve months (TTM), to the latest fiscal quarter end. Source: stored company filings and market data; unavailable inputs remain N/A.
Is the return on equity (ROE) high or low?
The return on equity (ROE) of -266.86% is 20% above its 4-year average of -334.28%, around the middle of its 4-year range (-749.08%–-25.88%).
As of the fiscal period ended Tuesday, June 30, 2026. 42.14% below its 12-month average of -187.75%.
Trailing-twelve-month return on equity at each fiscal quarter end; no daily interpolation. Q2 FY2026 (2026-06-30): -266.86%.
RETURN ON EQUITY (ROE)
-266.86%
RETURN ON EQUITY (ROE) AVG TTM
-187.75%
RETURN ON EQUITY (ROE) AVG 3Y
-267.71%
RETURN ON EQUITY (ROE) AVG 5Y
-334.28%
RETURN ON EQUITY (ROE) AVG 10Y
-212.31%
RETURN ON EQUITY (ROE) AVG 15Y
N/A
RETURN ON EQUITY (ROE) AVG 20Y
N/A
CURRENT VS TTM AVG
-42.14%
CURRENT VS 3Y AVG
+0.32%
CURRENT VS 5Y AVG
+20.17%
CURRENT VS 10Y AVG
-25.70%
CURRENT VS 15Y AVG
N/A
CURRENT VS 20Y AVG
N/A
SECTOR MEDIAN · HEALTHCARE
-39.92%
median of 594 covered companies
CURRENT VS SECTOR MEDIAN
-568.41%
vs the sector median at left
LifeMD, Inc.
Market Cap
$135.17M
Return on Equity (ROE)
-266.86%
TTM Avg
-187.75%
3Y Avg
-267.71%
5Y Avg
-334.28%
Market Cap
$136.52M
Return on Equity (ROE)
-775.59%
TTM Avg
-106.56%
3Y Avg
-86.72%
5Y Avg
-48.99%
Market Cap
$136.88M
Return on Equity (ROE)
-10.08%
TTM Avg
-25.77%
3Y Avg
-36.68%
5Y Avg
-27.09%
Market Cap
$132.82M
Return on Equity (ROE)
15.55%
TTM Avg
-9.97%
3Y Avg
-34.81%
5Y Avg
-26.89%
Market Cap
$139.63M
Return on Equity (ROE)
-44.26%
TTM Avg
-34.18%
3Y Avg
285.39%
5Y Avg
-5868.11%
Market Cap
$139.73M
Return on Equity (ROE)
68.12%
TTM Avg
-94.32%
3Y Avg
-166.28%
5Y Avg
-128.51%
Market Cap
$129.68M
Return on Equity (ROE)
-262.64%
TTM Avg
-45.72%
3Y Avg
-38.99%
5Y Avg
-37.83%
Market Cap
$141.83M
Return on Equity (ROE)
-11.20%
TTM Avg
-11.86%
3Y Avg
-12.45%
5Y Avg
-5.17%
| NAME | MARKET CAP | RETURN ON EQUITY (ROE) | TTM | 3Y | 5Y |
|---|---|---|---|---|---|
| LifeMD, Inc. (LFMD) | $135.17M | -266.86% | -187.75% | -267.71% | -334.28% |
| Freenome, Inc. (FRNM)vs › | $135.70M | N/A | N/A | N/A | N/A |
| Pyxis Oncology, Inc. (PYXS)vs › | $136.52M | -775.59% | -106.56% | -86.72% | -48.99% |
| KORU Medical Systems, Inc. (KRMD)vs › | $136.88M | -10.08% | -25.77% | -36.68% | -27.09% |
| Organigram Global Inc. (OGI)vs › | $132.82M | 15.55% | -9.97% | -34.81% | -26.89% |
| Alpha Cognition Inc (ACOG)vs › | $139.63M | -44.26% | -34.18% | 285.39% | -5868.11% |
| Fortress Biotech, Inc. (FBIOP)vs › | $139.73M | 68.12% | -94.32% | -166.28% | -128.51% |
| Health Catalyst, Inc. (HCAT)vs › | $129.68M | -262.64% | -45.72% | -38.99% | -37.83% |
| AirSculpt Technologies, Inc. (AIRS)vs › | $141.83M | -11.20% | -11.86% | -12.45% | -5.17% |
| Entera Bio Ltd. (ENTX)vs › | $128.15M | -234.42% | -102.69% | -100.55% | -100.92% |
ROE
-266.9%
ROA
-35.5%
ROE = Net Income / Total Shareholders' Equity
Return on equity measures how efficiently a company generates profit from shareholders' equity. Higher ROE indicates better capital efficiency.
Expanded definitions: Investopedia, Wikipedia, Corporate Finance Institute
| DATE | RETURN ON EQUITY (ROE) |
|---|---|
| 2026-06-30 | -266.86% |
| 2026-03-31 | -108.07% |
| 2025-12-31 | -25.88% |
| 2025-09-30 | -350.17% |
| 2023-12-31 | -587.56% |
| 2022-06-30 | -749.08% |
| 2022-03-31 | -359.78% |
| 2021-12-31 | -226.80% |
| 2019-03-31 | -625.84% |
| 2018-12-31 | -138.22% |
| 2018-09-30 | -59.70% |
| 2018-06-30 | -66.73% |
| 2018-03-31 | 41.12% |
| 2017-12-31 | -136.74% |
| 2017-09-30 | -196.34% |
| 2016-09-30 | -179.83% |
| 2016-06-30 | -109.50% |
| 2016-03-31 | -163.48% |
| 2015-12-31 | -61.94% |
| 2014-03-31 | -445.45% |
| 2013-12-31 | -137.23% |
| 2013-09-30 | -656.69% |
| 2013-06-30 | -159.77% |
| 2013-03-31 | -380.74% |
| 2012-12-31 | -330.10% |
